NEW YORK (GenomeWeb) – Rosetta Genomics today announced that its sales partner Admera Health has received approval from the New Jersey Department of Health (NJDH) for the OncoGxSelect panel for clinical use.

Admera's next-generation sequencing-based oncology panel looks at five genes associated with lung cancer. The test detects point mutations, small indels, and gene fusions in KRAS, BRAF, EGFR, ROS1, and ALK to provide clinically actionable results. OncoGxSelect is performed on formalin-fixed, paraffin-embedded tissue samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.